Latest Breaking News On - Safety results - Page 8 : comparemela.com

Ocuphire Pharma to Present at Euretina and Retina Society Conferences in October

Presentations Will Feature Data From ZETA-1 Phase 2 Trial of APX3330 in Diabetic RetinopathyFARMINGTON HILLS, Mich., Oct. 06, 2023 (GLOBE NEWSWIRE) Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced presentations featuring results from the ZETA-1 Phase 2 Trial of APX3330 at the 23rd Euretina Congress to take plac

United statesNew yorkNoord hollandVeeral shethCorey davisOcuphire pharmaRick rodgersViatris incAmsterdam convention centerOcuphire pharma incRetina society scientific meetingDrug administrationEuretina congressPresentations will feature data fromAnnual retina society scientific meetingDaily treatment

Boston Scientific : Position on FDA Update About Use of Paclitaxel-Coated Devices to Treat Peripheral Arterial Disease

On July 11, 2023, the U.S. Food and Drug Administration published a letter to healthcare providers stating that, based on its review of the totality of the available data and analyses,.

United statesMichaelr jaffMarianne brodmannBlake rouhaniLas vegasLauren tenglerDrug administrationBoston scientificPeripheral interventionsDrug eluting vascular stent systemDrug coated balloonTrial long term outcomesGermany junYear overall resultsRavish sacharLong lesion substudy

U S Food and Drug Administration Approves BioMarin s ROCTAVIAN™ (valoctocogene roxaparvovec-rvox), the First and Only Gene Therapy for Adults with Severe Hemophilia A

/PRNewswire/ BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, today.

United statesMarni kottleBiomarin rareconnectionsJeff ajerTraci mccartyInternational society on thrombosisRobust ongoing clinical programHemophilia treatment centers htcsPrnewswire biomarin pharmaceutical incBiomarin pharmaceutical incWarranty programExchange commissionDrug administrationReplay international numberInternational numberSingle dose treatment available

U S Food and Drug Administration Approves BioMarin s ROCTAVIAN™ (valoctocogene roxaparvovec-rvox), the First and Only Gene Therapy for Adults with Severe…

U S Food and Drug Administration Approves BioMarin s ROCTAVIAN™ (valoctocogene roxaparvovec-rvox), the First and Only Gene Therapy for Adults with Severe…
biztoc.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biztoc.com Daily Mail and Mail on Sunday newspapers.

Single dose treatment availableSevere hemophiliaSafety resultsLongest phaseGene therapyPatients continued

Ocuphire Presents APX3330 ZETA-1 Clinical Data in Late-Breaker Session at the American Diabetes Association s Annual Conference

Ocuphire Presents APX3330 ZETA-1 Clinical Data in Late-Breaker Session at the American Diabetes Association s Annual Conference
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

San diegoUnited statesVictorh gonzalezCorey davisRick rodgersOcuphire pharmaBret shapiroViatris incOcuphire pharma incScientific sessions of the american diabetes associationDaily treatmentSafety resultsDiabetic retinopathyScientific sessionsAmerican diabetes associationInterim chief executive